Oxford Biomedica PLC Director Dealings (3525I)
23 November 2018 - 9:41PM
UK Regulatory
TIDMOXB
RNS Number : 3525I
Oxford Biomedica PLC
23 November 2018
Director Dealings / Market Share Purchase
Oxford, UK - 23 November 2018: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, today announces that Dr. Lorenzo Tallarigo, Chairman
of the Group, has purchased 406 ordinary shares of 50p each
("Ordinary Shares") in the Company on 23 November 2018 on the
London Stock Exchange at a price of 653.9p per share as set out
below under the market share purchase agreement outlined in the
Group's announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr.
Tallarigo's fees as Chairman, after tax, are to be used to purchase
ordinary shares in Oxford BioMedica plc on a monthly basis at the
prevailing market price.
Following this purchase Dr. Tallarigo holds 47,539 ordinary
shares representing 0.07% of the Company.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of Ordinary Shares purchased.
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Lorenzo Tallarigo
2. Reason for the notification
a. Position/status Chairman
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford BioMedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford BioMedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Purchase of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP6.539 406
e. Aggregated information 406
* Aggregated volume GBP6.539
GBP2,654.83
* Price
* Aggregated total
f. Date of the transaction 2018-11-23
g. Place of the transaction London Stock Exchange, Main Market (XLON)
The issued share capital of the Group is 66,058,261 ordinary 50p
shares.
-Ends-
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Financial and corporate communications Tel: +44 (0)20 3709 5700
enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia
Manser/Laura Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R)), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Bioverativ, Sanofi, Axovant,
Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis
Gene Therapy Consortium and Imperial Innovations, GC LabCell and
Immune Design, through which it has long-term economic interests in
other potential gene and cell therapy products. Oxford BioMedica is
based across several locations in Oxfordshire, UK and employs more
than 360 people. Further information is available at
www.oxfordbiomedica.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHPGGBWGUPRGUW
(END) Dow Jones Newswires
November 23, 2018 05:41 ET (10:41 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024